Hidden Inflammation Trigger Exposed in Alzheimer’s Brains

A hand pointing at a brain MRI scan on a screen

Researchers at Scripps Research have pinpointed a specific molecular switch inside the brain that keeps Alzheimer’s immune cells permanently stuck in overdrive — and blocking it actually protected synapses in a living animal model.

Story Snapshot

A 2026 study identified a chemically altered protein called SNO-STING that forces the brain’s immune system into chronic inflammatory overdrive in Alzheimer’s disease.
Elevated SNO-STING was detected in postmortem Alzheimer’s brain tissue and in lab-grown human brain immune cells exposed to Alzheimer’s proteins.
Blocking the modification at a precise molecular site reduced neuroinflammation and protected synapses in a mouse model.
No human clinical trials exist yet, and the field’s long history of promising animal results that failed in people demands cautious optimism.

The Brain’s Immune System Has an Off Switch — Alzheimer’s Breaks It

The brain runs its own immune patrol through specialized cells called microglia. Under normal conditions, microglia detect threats, respond, and stand down. In Alzheimer’s disease, that stand-down signal never arrives. The microglia keep firing, flooding surrounding tissue with inflammatory signals that damage the very neurons they were meant to protect. Scientists have known this pattern exists for years. What they could not explain was the precise mechanism locking the system in the on position. That explanation may now be within reach.

Researchers at Scripps Research published findings in April 2026 identifying a protein called Stimulator of Interferon Genes, known in the field as STING, as the culprit behind this runaway inflammation. STING is a legitimate component of the brain’s antiviral defense, but in Alzheimer’s patients it appears to get chemically hijacked. The team found that a process called S-nitrosylation attaches a nitric oxide group to a specific location on the STING protein — a site called cysteine 148 — producing a corrupted version they labeled SNO-STING. This altered form drives STING to cluster and trigger excessive type I interferon signaling, essentially jamming the immune alarm in the fully activated position.

Human Brain Tissue Confirmed the Signal, Not Just Mouse Models

One detail separates this finding from the usual preclinical noise: the team did not stop at mice. Elevated SNO-STING appeared in postmortem brain tissue from actual Alzheimer’s patients and in human stem cell-derived brain immune cells exposed to Alzheimer’s proteins. ^[2] That human-tissue confirmation matters enormously. The graveyard of Alzheimer’s research is filled with mechanisms that looked bulletproof in rodents and vanished the moment researchers looked at human biology. Finding the same biochemical fingerprint in human samples gives the STING hypothesis a foothold that most preclinical claims never reach.

Independent work reinforces the biological logic. A separate study in a genetically engineered mouse model found that completely removing STING reduced amyloid beta accumulation, decreased microglial overactivation, and protected against cognitive decline. ^[4] A broader review of the cGAS-STING pathway across neurological conditions describes it as an upstream regulator of inflammatory signaling in the central nervous system, with relevance not only to Alzheimer’s but also to traumatic brain injury and other neurodegenerative disorders. ^[5] The convergence of multiple research lines on the same pathway is a meaningful signal, even if it is not proof of clinical utility.

Why Excitement Should Be Measured Against Alzheimer’s Track Record

The Alzheimer’s field has a brutal history with promising targets. Amyloid plaques were supposed to be the answer. Then tau tangles. Then neuroinflammation broadly defined. Each wave produced compelling preclinical data and devastating clinical trial failures. The STING hypothesis is more mechanistically specific than most of its predecessors — identifying a precise chemical modification at a named molecular site is a different level of resolution than pointing at a general inflammatory pathway — but specificity in a mouse does not guarantee success in a human brain that has been degenerating for a decade before diagnosis. ^[1]

The honest accounting of what remains unknown is long. No one has established whether SNO-STING is the initiating driver of Alzheimer’s inflammation or a downstream amplifier of damage already underway. ^[2] The right dose of STING suppression, the right brain cell types to target, and the right disease stage for intervention are all unresolved. Suppressing STING also carries a real concern: the protein plays a role in defending the brain against viruses, and any therapy that dials it down risks compromising that defense. A rigorous safety package will need to define the therapeutic window before any human trial can responsibly proceed. ^[5] What this discovery does offer is the most chemically precise target for Alzheimer’s neuroinflammation identified to date — a specific amino acid on a specific protein, modified by a specific chemical reaction, found in actual human disease tissue. ^[3] That is not a cure. It is a credible starting point, which in Alzheimer’s research is rarer than headlines suggest.